Abstract ‘ ‘
The poly lactate co-glycolic acid (PLGA) nanoparticles of tubercular
drugs have been demonstrated to have sustained release profile over
seven days. There is no information on the location or mode of release
of these nanoparticles in living system. Therefore, we have planned the
study to explore the pharmacokinetics and biodistribution of PLGA
rifampicin nanoparticles in healthy human volunteers.